Survey
Quarterly Survey: LR-MDS RBC Transfusions and treatments including Luspatercept and Epoetin Alfa April 2024
Ticker(s): BMY, GERN, ELRN, MRK, XLRNThe survey includes 20 Hematologists.
How many patients with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell transfusions do you treat?
How would you best describe your practice?
- Private
- Academic
- Community
How many LR-MDS patients requiring red blood cell transfusions are you currently treating with Epoetin Alfa?
How many LR-MDS patients requiring red blood cell transfusions are you currently treating with Luspatercept?
How many LR-MDS patients requiring red blood cell transfusions do you expect to start Epoetin Alfa in the next 30 days?
How many LR-MDS patients requiring red blood cell transfusions do you expect to start Luspatercept in the next 30 days?
What percentage (%) of your LR-MDS patients requiring red blood cell transfusions do you anticipate treating with Luspatercept at the following timepoints:
- In the next 6 months:
- In 1 year:
- In 3 years:
How would you rate Luspatercept the on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor access
- Patient willingness to try
How do you factor in the results of the RS- test when making treatment decisions for 2L RS- MDS patients?
Do the negative result in RS- impact your decision making when it comes to 2L RS- MDS?
Why or why not?
How do you expect fatigue as a side effect of the Luspatercept treatment to impact your use of the treatment?
How does Luspatercept compare to other available treatments on the market in treating LR-MDS patients requiring red blood cell transfusions?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Luspaterceptfor LR-MDS patients requiring red blood cell transfusions?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
